Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study A Giacomelli, L Pezzati, F Conti, D Bernacchia, M Siano, L Oreni, ... Clinical infectious diseases 71 (15), 889-890, 2020 | 1780 | 2020 |
Man-to-woman sexual transmission of HIV: longitudinal study of 343 steady partners of infected men A Saracco, M Musicco, A Nicolosi, G Angarano, C Arici, G Gavazzeni, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 6 (5), 497-502, 1993 | 359 | 1993 |
Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy C Gervasoni, AL Ridolfo, G Trifirò, S Santambrogio, G Norbiato, ... Aids 13 (4), 465-471, 1999 | 351 | 1999 |
Clinical features and outcomes of HIV patients with coronavirus disease 2019 C Gervasoni, P Meraviglia, A Riva, A Giacomelli, L Oreni, D Minisci, ... Clinical Infectious Diseases 71 (16), 2276-2278, 2020 | 210 | 2020 |
Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV C Hoffmann, JL Casado, G Härter, P Vizcarra, A Moreno, D Cattaneo, ... HIV medicine 22 (5), 372-378, 2021 | 188 | 2021 |
Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors M Galli, AL Ridolfo, F Adorni, C Gervasoni, L Ravasio, L Corsico, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 29 (1), 21-31, 2002 | 181 | 2002 |
Clinical features and outcomes of patients with human immunodeficiency virus with COVID-19 C Gervasoni, P Meraviglia, A Riva, A Giacomelli, L Oreni, D Minisci, ... Clinical Infectious Diseases 71 (16), 2276-2278, 2020 | 131 | 2020 |
Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study M Galli, A Cozzi-Lepri, AL Ridolfo, C Gervasoni, L Ravasio, L Corsico, ... Archives of Internal Medicine 162 (22), 2621-2628, 2002 | 117 | 2002 |
Direct‐acting antivirals in hepatitis C virus (HCV)‐infected and HCV/HIV‐coinfected patients: real‐life safety and efficacy L Milazzo, A Lai, E Calvi, P Ronzi, V Micheli, F Binda, AL Ridolfo, ... HIV medicine 18 (4), 284-291, 2017 | 104 | 2017 |
Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy C Gervasoni, AL Ridolfo, M Vaccarezza, C Parravicini, L Vago, F Adorni, ... Clinical infectious diseases 35 (12), 1534-1540, 2002 | 100 | 2002 |
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational study RK Lodwick, CA Sabin, K Porter, B Ledergerber, A Van Sighem, ... The Lancet 376 (9738), 340-345, 2010 | 98 | 2010 |
Invasive fungal infections complicating COVID-19: a narrative review G Casalini, A Giacomelli, A Ridolfo, C Gervasoni, S Antinori Journal of Fungi 7 (11), 921, 2021 | 82 | 2021 |
Polymerase chain reaction for Toxoplasma gondii DNA in the cerebrospinal fluid of AIDS patients with focal brain lesions R Novati, A Castagna, G Morsica, L Vago, G Tambussi, S Ghezzi, ... Aids 8 (12), 1691-1694, 1994 | 77 | 1994 |
Darunavir does not prevent SARS-CoV-2 infection in HIV patients A Riva, F Conti, D Bernacchia, L Pezzati, S Sollima, S Merli, M Siano, ... Pharmacological research 157, 104826, 2020 | 75 | 2020 |
A comparision of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients AA Monforte, P Cinque, L Vago, A Rocca, A Castagna, C Gervasoni, ... Journal of neurology 244, 35-39, 1996 | 72 | 1996 |
Immunoendocrinologic abnormalities in human immunodeficiency virus infection M Clerici, M Galli, S Bosis, C Gervasoni, M Moroni, G Norbiato Annals of the New York Academy of Sciences 917 (1), 956-961, 2000 | 69 | 2000 |
Inter-and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects D Cattaneo, C Gervasoni, P Meraviglia, S Landonio, S Fucile, V Cozzi, ... Journal of antimicrobial chemotherapy 67 (2), 460-464, 2012 | 66 | 2012 |
Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse events C Gervasoni, P Meraviglia, S Landonio, S Baldelli, S Fucile, L Castagnoli, ... PLoS One 8 (12), e80242, 2013 | 62 | 2013 |
Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected withLeishmania infantum AL Ridolfo, C Gervasoni, S Antinori, M Pizzuto, S Santambrogio, ... Journal of Infection 40 (2), 199-202, 2000 | 62 | 2000 |
Therapeutic drug management of linezolid: a missed opportunity for clinicians? D Cattaneo, C Gervasoni, V Cozzi, S Castoldi, S Baldelli, E Clementi International journal of antimicrobial agents 48 (6), 728-731, 2016 | 58 | 2016 |